Building a biobank to unlock radiation Therapy's secrets
NCT ID NCT00992303
First seen Jul 17, 2026 · Last updated Jul 17, 2026
Summary
This research study collects tissue samples and medical information from people with cancer who are receiving radiation therapy, as well as from healthy volunteers. The goal is to create a long-term resource that scientists can use to study how cancer responds to radiation and to compare findings with healthy tissue. Participation involves donating samples and allowing researchers to review medical records over time.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- The collected samples and data could help researchers better understand how cancer responds to radiation therapy and improve future treatments.
- What could go wrong
- This is a tissue and data collection study, not a treatment trial, so it does not directly test any new therapy. Results depend on future analyses.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 10,000 people
The number the study aims to enrol. It can still change while the study runs.
- Start date
-
Sep 2009
- Expected to finish
-
Dec 2029
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Cancer patients, healthy volunteers
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
DISEASE CHARACTERISTICS: * Pathologically-proven diagnosis of malignancy * Planning treatment with radiation therapy PATIENT CHARACTERISTICS: * Able to perform follow-up visits * Is a patient of the University of Texas Southwestern Medical Center physicians PRIOR CONCURRENT THERAPY: * See Disease Characteristics * Participation in other clinical trials is allowed * Other prior or concurrent therapy for cancer, such as surgery and/or chemotherapy, is allowed. Criteria for eligibility: * Able to provide written informed consent * Age greater than 18 years old * Males and Females are eligible * Any ethnicity is eligible Criteria for ineligibility: -Patients not available for follow-up/future contact
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Unspecified adult solid tumor, protocol specific are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
UT Southwestern Medical Center
RECRUITINGDallas, Texas, 75390, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Tumor DNA mapping may unlock personalized cancer therapies
- Can a new tracer light up cancer growth?
- Experimental drug COH29 targets tumor growth enzyme in advanced cancers
- PET-CT scans could sharpen radiation targeting for liver tumors
- New registry aims to unlock secrets of cancer in older adults
- New radiation dosing strategy aims to tame large brain metastases